5H-pyrazolo[5,1-b][1,3]oxazine

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 5H-pyrazolo[5,1-b][1,3]oxazine
• 化学式: C₆H₆N₂O
• 分子量: 122.12
• InChiKey: BATHSJXWLINJCT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  27
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• [EN] CASEIN KINASE 1 DELTA MODULATORS<br/>[FR] MODULATEURS DE LA CASÉINE KINASE 1 DELTA
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2022058920A1

  公开（公告）日：2022-03-24

  A compound of Formula (I), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with casein kinase 1 delta (CSNK1D) modulation, such as those associated with mood/psychiatric disorders, neurodegenerative diseases, cancers, addiction and substance abuse disorders, pain, and metabolic diseases.Wherein R1, R2, R3, and R4, are defined herein.

  一种化合物公式(I)，包含它们的药物组合物，制备它们的方法，以及使用它们的方法，包括用于治疗与酪氨酸激酶1δ(CSNK1D)调节相关的疾病状态、障碍和病情的方法，例如与情绪/精神障碍、神经退行性疾病、癌症、成瘾和物质滥用障碍、疼痛和代谢性疾病相关的方法。其中，R1、R2、R3和R4在此定义。
• 6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds
  申请人：Pfizer Inc.

  公开号：US10323042B2

  公开（公告）日：2019-06-18

  The present invention is directed to compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein the substituents R1, R2, R3, and R4 are as defined herein. The invention is also directed to pharmaceutical compositions comprising the compounds, methods of treatment using the compounds, and methods of preparing the compounds.

  本发明涉及式 I 的化合物： 或其药学上可接受的盐，其中取代基 R1、R2、R3 和 R4 如本文所定义。本发明还涉及包含这些化合物的药物组合物、使用这些化合物的治疗方法以及制备这些化合物的方法。
• SULFONIMIDAMIDE COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY
  申请人：F. Hoffmann-La Roche AG

  公开号：EP3823974A1

  公开（公告）日：2021-05-26
• US20140256677A1
  申请人：——

  公开号：US20140256677A1

  公开（公告）日：2014-09-11
• 6,7-DIHYDRO-5H-PYRAZOLO[5,1-B][1,3]OXAZINE-2-CARBOXAMIDE COMPOUNDS
  申请人：Pfizer Inc.

  公开号：US20190055262A1

  公开（公告）日：2019-02-21

  The present invention is directed to compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein the substituents R 1 , R 2 , R 3 , and R 4 are as defined herein. The invention is also directed to pharmaceutical compositions comprising the compounds, methods of treatment using the compounds, and methods of preparing the compounds.